CRISPRShutterstock/vchal

  • The FDA just put a hold on one of the first trials to test the CRISPR gene-editing technology in humans. The trial hadn't begun yet.
  • The trial, run by CRISPR Therapeutics and Vertex Pharmaceuticals, plans to look at how the gene-editing technology works to treat patients with sickle cell disease. The trial has been put on hold "pending the resolution of certain questions that will be provided by the FDA."

Screen Shot 2018 05 30 at 5.55.28 PMMarkets Insider

Visit Markets Insider for constantly updated market quotes for individual stocks, ETFs, indices, commodities and currencies traded around the world. Go Now!

{{}}